- Understanding the increasing trend of combining medical devices and drugs
- Gaining insights from the European Medicines Agency (EMA) on the future of medical device and drug combinations
- Explaining the distinction between Medical Devices Regulation (MDR) and Medical Devices Directive (MR) for combination products
- Identifying compliance requirements and implications based on the device’s primary mode of action
- Presenting various regulatory pathways available for combination products
- Understanding how partnerships can drive innovation and development in this domain
Archives: Agenda
Building a strong foundation: robust, scalable, clinical trials platform for Medtech
This session will explore the pivotal role of clinical technology and AI in driving the success of Medtech trials, focusing on how a unified, AI-enabled platform can serve as the foundation for an expanded data health ecosystem. Attendees will learn the benefits of interconnected data flows, starting with purpose-built, simple electronic data capture (EDC) systems for Medtech trials, scaling by integrating Imaging capabilities, leveraging AI for enhanced data analysis, and enabling seamless one-click imports of Electronic Health Records (EHRs). This approach eliminates redundancies, enhances data integrity, reduces site burden, and can bridge clinical trial data with real-world evidence to improve device observation and long-term insights. By adopting an integrated, AI-driven platform, sponsors can meet current trial demands while building a robust data ecosystem to advance future patient care.
- Recognize the importance of choosing a scalable platform to future-proof clinical trials and enable seamless connections between trial data and real-world evidence for long-term impact
- Understand the role of a unified cloud-based platform in creating a connected data health ecosystem tailored to Medtech trials
- Explore how integrating Imaging and EHR data can enhance operational efficiency, data accuracy, and site engagement
Morning refreshments and networking
CASE STUDY AI and software-as-a-medical product development and commercialization: challenges and new developments
- Navigating the evolving regulatory landscape for AI and software as medical devices
- Integrating AI into existing healthcare systems
- Managing the lifecycle of AI products
- Gaining clinical experience by users of AI based SaMDs
Registration and refreshments
Streamlining success: navigating preclinical to pre-market pathways for study approval
Navigating the journey from preclinical studies to market approval is a critical and complex process for medical devices. This presentation outlines a streamlined approach to ensure regulatory compliance, efficient development, and timely market access
- The importance of correct device classification and its impact on regulatory pathways.
- Strategies to define a comprehensive regulatory roadmap tailored to global requirements.
- Key preclinical tests to establish safety and performance baselines
- Insights into aligning preclinical findings with a robust clinical protocol
- Criteria for selecting the right Notified Body to streamline certification
- Best practices for creating a well-structured technical file to facilitate regulatory review
Chairperson’s opening remarks
Panel discussion: Beyond the Agency: From Oversight to Insight
- Strategic insights for the incoming CTP Director
- Experience-based recommendations for improving internal processes
- Recommendations for industry stakeholders on building and sustaining trust through effective communication with CTP
Moderator: Willie McKinney, Ph.D. Founder & CEO, McKinney Regulatory Science Advisors, LLC
Panelists
Dr. Roxana Weil, Chief Regulatory Science Officer, McKinney Specialty Labs
Gabriel Muñiz, Owner & Principal Consultant, QualReg Solutions LLC
Angela Ho-Chen, Managing Counsel – Regulatory, Reynolds American
Melis Coraggio, Consultant, King & Spalding LLP
David Oliveira, Partner, Scrimshaw Strategies
Panel Discussion: A Bug in The System: AI Agents in a Crypto World
- The proliferation of AI agents within the crypto community
- How can AI agents used in reality and where are the used cases?
- Successful strategies vs Trial and error stories
Moderator: Bhavin P. Kapadia, Senior Advisor – Financial Services, AIFS Series Advisory Board
Panel Discussion: Rewriting The Cultural Adoption of AI and Automation
- How do you perceive the current state of AI and automation adoption?
- Exploring communication techniques to maintain a balanced level of integrated AI strategies and initiatives
- Productionising GenAI – is it giving the right information?
Moderator: Isabel Al-Dhahir